Janssen Pharmaceuticals Inc.
1125 Trenton-Harbourton Road
P.O. Box 200
Titusville
NJ
08560
800-775-5514
http://www.janssenpharmaceuticalsinc.com/

Related Content

COMPASS open label extension study results support the long-term use of XARELTO plus aspirin for vascular protection in patients with chronic CAD and/or PAD
News | Cardiovascular Clinical Studies
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition with XARELTO Plus Aspirin in Patients with Coronary Artery Disease, Peripheral Artery Disease

May 31, 2022 — Findings from the XARELTO (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and ...

Home May 31, 2022
arrow
CDC and FDA Call for Pause on Janssen COVID-19 Vaccine Due to Rare Blood Clots #COVID19 #Janssen
Feature | Coronavirus (COVID-19)| By Dave Fornell, Editor
CDC and FDA Call for Pause on Janssen COVID-19 Vaccine Due to Rare Blood Clots

(This story was updated May 7, 2021 in the last subheaded section) April 13, 2021 — The U.S. Food and Drug ...

Home April 13, 2021
arrow
FDA Clears Third COVID-19 Vaccine From Janssen, Johnson and Johnson, J&J
News | Coronavirus (COVID-19)
FDA Clears Third COVID-19 Vaccine From Janssen

March 1, 2021 — The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the third ...

Home March 01, 2021
arrow
Rivaroxaban (Xeralto) is now cleared by the FDA with a new indication is for patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).
Technology | Antiplatelet and Anticoagulation Therapies
FDA Clears Rivaroxaban to Reduce the Risk of Major Cardiovascular Events

October 17, 2018 — The U.S. Food and Drug Administration (FDA) has cleared an additional indication for rivaroxaban ...

Home October 17, 2018
arrow
Xarelto Associated With Reduced Hospital Time and Costs for Low-risk PE Patients
News | Pulmonary Embolism
Xarelto Associated With Reduced Hospital Time and Costs for Low-risk PE Patients

June 29, 2018 — Results from the MERCURY PE study showed that low-risk pulmonary embolism (PE) patients treated with ...

Home June 29, 2018
arrow
The Xarelto booth at ACC.18
News | Antiplatelet and Anticoagulation Therapies
COMPASS Trial Shows Rivaroxaban and Aspirin Lowers Major Adverse Limb Events in Peripheral Artery Disease

March 14, 2018 — A late-breaking analysis of the landmark COMPASS study presented at the American College of Cardiology ...

Home March 14, 2018
arrow
Xarelto Reduces Ischemic Stroke for Coronary and Peripheral Artery Disease Patients
News | Antiplatelet and Anticoagulation Therapies
Xarelto Reduces Ischemic Stroke for Coronary and Peripheral Artery Disease Patients

February 19, 2018 — A late-breaking analysis of the landmark COMPASS study was presented at the 2018 International ...

Home February 19, 2018
arrow
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals
Xarelto Significantly Reduces Major Cardiovascular Events in Stable CAD and PAD Patients

October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the Xarelto vascular dose plus aspirin 100 ...

Home October 18, 2017
arrow
FDA Grants Priority Review of Xarelto sNDA for 10 mg Dose
News | Antiplatelet and Anticoagulation Therapies
FDA Grants Priority Review of Xarelto sNDA for 10 mg Dose

June 29, 2017 — Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) accepted for ...

Home June 29, 2017
arrow
Xarelto, rivaroxaban, COMPASS study, ends early,
News | Antiplatelet and Anticoagulation Therapies
Rivaroxaban Shows Superiority Over Aspirin in Patients With Coronary and Peripheral Artery Disease

February 9, 2017 — Janssen Research & Development LLC (Janssen) announced that the Phase 3 COMPASS trial is stopping ...

Home February 09, 2017
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now